Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andreas du BoisGroupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

Abstract

Despite the progress that has been achieved, long-term survival rates in patients with advanced ovarian cancer are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to platinum-paclitaxel combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. We performed a prospectively randomized phase III study comparing carboplatin-paclitaxel (TC; area under the curve 5/175 mg/m2, respectively) with epirubicin 60 mg/m2 added to the same combination (TEC) in previously untreated patients with advanced epithelial ovarian cancer. All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. Between November 1997 and February 2000, 1,282 patients were randomly assigned to receive either TC (635 patients) or TEC (647 patients), respectively. Grade 3/4 hematologic and some nonhematologic toxicities (nausea/emesis, mucositis, and infections) occurred significantly more frequently in the TEC arm. Accordingly, quality-of-life analysis showed inferiority of TEC versus TC. Median progression-free survival time was 18.4 months for the TEC arm and 17.9 months for the TC arm (hazard ratio...Continue Reading

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Oct 1, 1973·Annals of Internal Medicine·R W Jelliffe
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P A'Hern, M E Gore
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K KobayashiK Yoshida
May 9, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproJ B Vermorken
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Dec 17, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A BookmanR F Ozols
Jul 19, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·F HilpertUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

❮ Previous
Next ❯

Citations

Mar 8, 2013·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A González MartínA Poveda Velasco
Feb 22, 2013·Nature Reviews. Cancer·Emma KippsStan B Kaye
Apr 1, 2010·Nature Reviews. Clinical Oncology·Thomas Hogberg
May 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AlexandreUNKNOWN GINECO
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Bookman
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Aug 3, 2006·Journal of the National Cancer Institute·William P McGuire
Feb 22, 2012·Clinical Obstetrics and Gynecology·Michael A Bookman
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Monica BaconUNKNOWN Gynecologic Cancer InterGroup and participants of 4th Ovarian Cancer Consensus Conference
Jan 26, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Andreas du BoisJalid Sehouli
Aug 9, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Lisa M Hess, Frederick B Stehman
Oct 3, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A du BoisUNKNOWN Norddeutsche Gesellschaft Fuer Gynaekologische Onkologie [NOGGO]
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M S ManoA Awada
Apr 11, 2008·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M A Bookman
Dec 7, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M J Palayekar, T J Herzog
May 13, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mark S CareyBryan T Hennessy
Feb 8, 2013·Journal of Ovarian Research·Nicoletta StaropoliPierosandro Tagliaferri
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A BookmanLawrence M Roth
Jan 29, 2011·International Journal of Women's Health·Sanjeev KumarAdnan Munkarah
Dec 18, 2008·Future Oncology·Dirk O BauerschlagJakobus Pfisterer
Jul 6, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E C GrendysT J Herzog
Aug 10, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Elfriede R GreimelUNKNOWN Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO)
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Michael A Bookman
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Dana M Chase, Lari Wenzel
Dec 18, 2009·Expert Review of Anticancer Therapy·Claudia MarchettiSandro Pignata
Dec 18, 2009·Expert Review of Anticancer Therapy·Philipp HarterAndreas du Bois
Feb 5, 2013·Expert Opinion on Biological Therapy·Umberto Leone Roberti MaggioreSimone Ferrero
Mar 29, 2012·Expert Opinion on Drug Delivery·Payam ZahediChristine Allen
Sep 4, 2008·Expert Opinion on Emerging Drugs·Toru Sugiyama, Ikuo Konishi
Apr 7, 2010·Expert Opinion on Investigational Drugs·Liz Y HanStan B Kaye
Feb 24, 2009·Current Medical Research and Opinion·Jalid Sehouli, Gülten Oskay-Ozcelik
Oct 24, 2013·Systems Biology in Reproductive Medicine·Batoul Y AbdallahHenry H Q Heng
Nov 23, 2015·The Lancet Oncology·Andreas du BoisUNKNOWN AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consort
Apr 25, 2012·Gynecologic Oncology·Marcela G del CarmenJohn O Schorge
Sep 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Michael A Bookman
Apr 17, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Roshan AgarwalUNKNOWN Scottish Gynecological Cancers Trials Group
Nov 12, 2015·Critical Reviews in Oncology/hematology·Nicoletta ColomboGiovanni Scambia
Jan 9, 2010·Gynecologic Oncology·Valentina GuarneriPier Franco Conte

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of the National Cancer Institute
Andreas du BoisArbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andreas du BoisJalid Sehouli
The New England Journal of Medicine
Deborah K ArmstrongGynecologic Oncology Group
© 2021 Meta ULC. All rights reserved